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A B S T R A C T
Background
Stored glycogen is an important source of energy for skeletal muscle. Human genetic
disorders primarily affecting skeletal muscle glycogen turnover are well-recognised, but rare.
We previously reported that a frameshift/premature stop mutation in PPP1R3A, the gene
encoding RGL, a key regulator of muscle glycogen metabolism, was present in 1.36% of
participants from a population of white individuals in the UK. However, the functional
implications of the mutation were not known. The objective of this study was to characterise
the molecular and physiological consequences of this genetic variant.
Methods and Findings
In this study we found a similar prevalence of the variant in an independent UK white
population of 744 participants (1.46%) and, using in vivo 13C magnetic resonance spectroscopy
studies, demonstrate that human carriers (n¼ 6) of the variant have low basal (65% lower, p¼
0.002) and postprandial muscle glycogen levels. Mice engineered to express the equivalent
mutation had similarly decreased muscle glycogen levels (40% lower in heterozygous knock-in
mice, p , 0.05). In muscle tissue from these mice, failure of the truncated mutant to bind
glycogen and colocalize with glycogen synthase (GS) decreased GS and increased glycogen
phosphorylase activity states, which account for the decreased glycogen content.
Conclusions
Thus, PPP1R3A C1984DAG (stop codon 668) is, to our knowledge, the first prevalent mutation
described that directly impairs glycogen synthesis and decreases glycogen levels in human
skeletal muscle. The fact that it is present in ;1 in 70 UK whites increases the potential
biomedical relevance of these observations.
The Editors’ Summary of this article follows the references.
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Introduction
The dissection of the genetic basis for interindividual
variation in human metabolism is a major goal of contem-
porary metabolic research. Recently we identiﬁed a novel
frameshift (FS) premature stop mutation in PPP1R3A
(C1984DAG; stop codon 668; referred to subsequently as
PPP1R3A FS [1]), a gene encoding the muscle-speciﬁc
glycogen-targeting subunit RGL (also called GM) of protein
phosphatase 1 (PP1) [2,3]. The RGL polypeptide contains an
extended C-terminal tail with a short hydrophobic segment
responsible for association with the sarcoplasmic reticulum
[4] as well as carbohydrate- (glycogen) [5] and PP1-binding
domains [6] in the N-terminal 240 residues. The latter
facilitate localization of the catalytic subunit of the phospha-
tase (PP1c) to glycogen where it dephosphorylates glycogen
synthase (GS) and glycogen phosphorylase (GP), and thereby
promotes glycogen synthesis [7–9]. We have previously shown
that Ppp1r3a-disrupted mice exhibit a 90% reduction in
muscle glycogen [10], whereas RGL-overexpressing mice
accumulate excess glycogen in muscle [11]. The PPP1R3A FS
mutation, which was initially described in a large white
kindred, results in a mutant protein lacking the long C-
terminal tail including the hydrophobic segment that tethers
it to the sarcoplasmic reticulum [4]. In that pedigree, severe
insulin resistance was restricted to individuals who were
doubly heterozygous for the PPP1R3A FS variant and an
unlinked loss-of-function mutation in PPARG (AAA553T;
stop codon 186), which encodes a key transcriptional
regulator of adipocyte differentiation [1]. Whilst the PPARG
variant was uniquely present in that kindred, the allelic
frequency of the PPP1R3A FS variant was 1.36% in a
population of UK whites. Although the truncated RGL was
shown to be mistargeted within the cell, its functional impact
on glycogen synthesis was not determined. Here we sought to
characterise the molecular and in vivo biological consequen-
ces of the PPP1R3A FS variant.
Methods
All human studies were approved by the relevant Local
Research Ethics Committees (Cambridge, Oxford, and Not-
tingham), and all participants provided written informed
consent. The RGL kin mice were generated by Cheryl Bock at
the Comprehensive Cancer Center Transgenic Facility, Duke
University, Durham, North Carolina, United States. All
animals were maintained on a 12:12 h light–dark cycle in a
temperature- and humidity-controlled facility with free
access to food and water. All mouse studies were conducted
in accordance with federal guidelines and were approved by
the Institutional Animal Use and Care Committees of
Indiana, Duke, and Yale Universities.
Oxford Biobank and Genotyping
The Oxford Biobank consists of an age-stratiﬁed random
sample of 30- to 50-year-old men and women from
Oxfordshire (total population 615,200) [12]. All participants
screened were classiﬁed as ‘‘white’’ by the researchers.
Exclusion criteria included mental or physical ill health,
alcohol- or drug-related problems, and signiﬁcantly abnormal
liver or renal function tests or anaemia. Participants attended
a screening visit at the Clinical Research Unit, where blood
tests were performed and basic anthropometric data
recorded. DNA was stored from the visit and consent
obtained to allow subsequent genotyping for genetic variants
of potential metabolic importance. Primer sequences used
for genotyping are available upon request.
Determination of Muscle Glycogen Concentration in
Human Participants
Six volunteers with the PPP1R3A FS mutation were studied
(Table 1). Two of these individuals were doubly heterozygous
for an additional unlinked mutation in PPARG and had
severe insulin resistance. The results from these individuals
were compared to volunteers without diabetes (n ¼ 9) and
participants with diet-controlled type 2 diabetes (n¼ 9) from
a previous study [13]. Participants abstained from vigorous
exercise and alcohol for 3 d prior to the study and each fasted
for 12 h prior to the study. Baseline 13C measurements for
muscle glycogen were taken prior to the ﬁrst standard meal (t
¼ 0), which consisted of 190.5 g carbohydrate, 41.0 g fat, and
28.8 g protein, totalling 1,253 kcal. Further measurements
were taken at 60, 120, and 240 min, after which another
standard meal of similar composition was given, followed by
measurements at 300, 360, and 480 min. All glycogen
measurements were performed at 3.0T, using a circular 13C
surface coil and quadrature 1H coils as described previously
[13]. Blood samples were taken for glucose and insulin
measurements at the same times as the spectra.
Generation of Mutant, RGL Knock-in Mice
The Ppp1r3a targeting vector was assembled by PCR-
ampliﬁed and restriction enzyme–digested fragments from
the k Fix 14-1-1 ES cell genomic DNA clone previously
reported [2]. This clone is 13 kb and extends from 2 kb
upstream of exon 2 to 7 kb downstream of the RGL stop
codon. The short recombination arm fragment consists of 1.2
kb of intron 3 and was inserted upstream of the 59 LoxP site
ﬂanking the Neo cassette at the XhoI and NotI sites in the
pPGKNeobpAlox2PGKDTA (Figure S1). The long recombi-
nation arm containing the FS mutation was constructed with
three fragments. Part 1 was engineered to contain the FS
premature stop codon found in the human participants at
the corresponding position in the mouse Ppp1r3a by
amplifying a region from 500 bp upstream of exon 4 to ;
1,000 bp of exon 4. The following oligonucleotide primers
were used: forward 59-TTTGCTAGCGCCGTTGACAAGTAA-
Table 1. Demographic Characteristics of the Study Participants
Characteristic PPP1R3A FS
carriers (4M, 2F)
Controls
(5M, 4F)
Diabetic
(6M, 3F)
Age, y 37.3 6 5.7 51.3 6 4.1 52.2 6 3.1
Body mass index, kg/m2 25.4 6 2.1 29.0 6 1.4 29.2 6 1.2
Glucose, mmol/l 4.7 6 0.2 4.5 6 0.1 7.1 6 0.5
TG, mmol/l 0.8 6 0.2a 1.4 6 0.2 2.9 6 0.7
TC, mmol/l ND 5.2 6 0.3 5.5 6 0.2
Data represent mean 6 SEM.
aThese data refer to four single heterozygous PPP1R3A FS carriers only. Double
heterozygotes for the PPP1R3A FS and PPARG FS were severely insulin resistant (see
Figure 1) and hypertriglyceridaemic. F, female; M, male; ND, not done; TC, total
cholesterol; TG, triglyceride.
doi:10.1371/journal.pmed.0050027.t001
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CATGAGCCTTAT-39 and reverse 59-AAACCATGGT-
TATTCTCTCTTGATTTTCCGGGTTTCCAGAACGTTC-
CATTT-39. The reverse primer encodes the altered six amino
acids found in the human mutation followed by a stop codon
and an NcoI site. Part 2 was a 2.2 kb NcoI-BstEII ampliﬁed
fragment. Part 3 was the 4.6 kb restriction enzyme–digested
BstEII-BStz171. The three fragments, totalling 8.3 kb, were
inserted downstream of the 39 LoxP site ﬂanking the PGK-
Neo gene at the NheI and EcoRV sites. Part 1 was completely
sequenced to ensure that the correct mutation was intro-
duced and that no unintended mutations were present. All
junctions in the ﬁnal construct were conﬁrmed by sequenc-
ing and restriction enzyme digestion. The RGL kin targeting
vector also contains the diphtheria toxin A gene (PGK-DTA)
for selection against random integration. The vector was
linearized at the unique AhdI site and electroporated into
W4 ES cells. G418-resistant cell clones were initially screened
for targeting by PCR with primers ADPR 424, 59-GCTA-
GACTTGATGGTAAGTGTTCTGGTTGCACAG-39 outside
of the short recombination arm and ADPR 422, 59-
CGCGAAGGGGCCACCAAAGAAGGGAGCCGGTTG-39, in
the PGK-Neo region. Positive clones were further analyzed
for the presence of the mutation by utilizing ADPR 425, 59-
CCCCGGAAATCAAGAGAGAATAACCATGG-39, which spe-
ciﬁcally recognizes the mutated sequence and not the cor-
responding wild type (WT), and ADPR 406, 59-
TGCGAATTCTCACCTGCCTTGAGCTTCGAGTTC-39 lo-
cated downstream. From this double screen, two positive
clones were identiﬁed and correct targeting was conﬁrmed
by Southern blots of ES cell genomic DNA digested with
NheI. Two fragments of 10.3 and 3.4 kb, corresponding to the
WT and to the targeted allele, respectively, were detected
with the 59 probe, and 10.3 kb and 8.8 kb fragments with the
39 probe (Figure S2A). Both clones, conﬁrmed to be correctly
targeted, were expanded and electroporated with a PGK-
NLS/Cre plasmid. Resulting clones were screened by PCR for
excision of the Neo cassette (efﬁciency 40%, 73/190) and 12
were analyzed and conﬁrmed by Southern blot (Figure S2B).
Two clones, after karyotyping, were injected into C57Bl/6J
blastocysts, which were then implanted in the uterus of
pseudopregnant female mice. High-percentage male chimer-
ic mice, as judged by the agouti colour coat, were mated with
C57Bl/6J mice to determine germline transmission. F1 mice
were backcrossed two more times into the C57Bl/6J back-
ground, before breeding the RGL kin heterozygotes to
generate animals used in the study. Mice were genotyped
by PCR with a pair of primers that straddle the residual loxP
site as well as a pair of primers, one of which speciﬁcally
hybridizes with the mutated nucleotides (Figure S2C).
Enzyme Activity Assays
The GS and GP activities were measured as previously
described [10]. Basically, powdered frozen tissue samples were
homogenized in 30 volumes of buffer (50 mM Tris-HCl [pH
7.8], 10 mM EDTA, 2 mM EGTA, 100 mM NaF, 2 mM
benzamidine, 0.1 mM Na-p-tosyl-L-lysine chloromethyl ke-
tone, 50 mM b-mercaptoethanol, 0.5 mM PMSF, and 10 lg/ml
leupeptin) using a Tissue Tearer Model 285–370 (Biospec
Products) at maximal speed for 20 s. After centrifugation at
3,600g for 5 min, 30 ll of the supernatant was used for GS and
GP assays. GS activity was determined by measuring
incorporation of [14C]glucose from UDP-[14C]glucose into
glycogen as described by Thomas et al. [14] in the absence or
presence of 7.2 mM glucose-6-phosphate (G6P). GP activity
was assayed by measuring incorporation of [14C]glucose from
[14C]glucose-1-phosphate into glycogen in the absence or
presence of 2 mM AMP [15]. One unit of GS is the amount of
enzyme that incorporates 1 lmol/min of 14C-glucose from
UDP-[U-14C]glucose into glycogen and 1 unit of GP, the
amount of enzyme that incorporates 1 lmol/min of [14C]glu-
cose from [U-14C]glucose-1-phosphate. Activity ratios repre-
sent the activity measured in the absence divided by that in
the presence of the allosteric effectors G6P for GS or AMP for
GP and provide an index of the phosphorylation state and
hence, activity of the enzymes.
Other procedures. Information about Western immuno-
blotting, immunoprecipitations, GST-GN pull-downs, glyco-
gen pellets, glucose and insulin tolerance tests, and
hyperinsulinemic-euglycemic clamps is included in Text S1.
Statistical Analysis
All data are expressed as mean 6 standard error of the
mean (SEM). Two-tailed Student t-tests or one-way ANOVA
plus Tukey HSD multiple comparisons were performed on
data at a minimum p , 0.05 threshold.
Results
The PPP1R3A FS Mutation Is Prevalent in UK Whites and
Impairs In Vivo Glycogen Synthesis
We genotyped 744 adults without diabetes from an
Oxfordshire Biobank and found that the PPP1R3A FS allelic
frequency was 1.46%. To determine the in vivo effects of this
truncated variant on skeletal muscle glycogen synthesis, 13C
magnetic resonance spectroscopy studies were undertaken in
nondiabetic volunteers of known genotype from the Oxford-
shire study. Baseline muscle glycogen concentration (23.9 6
14.7 mmol/l) was signiﬁcantly lower (65%, p ¼ 0.002) in
PPP1R3A FS heterozygotes than in nondiabetic volunteers
(68.9 6 4.1 mmol/l) and even volunteers with type 2 diabetes
(57.1 6 3.6 mmol/l, p ¼ 0.01) (Figure 1A) [13]. After a meal,
mean glycogen concentrations increased in nondiabetic
volunteers (97.1 6 7.0 mmol/l at 240 min; p¼ 0.005). Glycogen
levels peaked at 108.0 6 11.6 mmol/l after a second meal
(Figure 1A). This response was blunted in PPP1R3A FS
carriers. Despite the signiﬁcant differences in muscle
glycogen levels, plasma glucose and insulin measurements
were similar in nondiabetic volunteers and PPP1R3A FS
carriers (Figure 1B and 1C). Muscle glycogen concentrations
were decreased to a similar extent in two severely insulin-
resistant individuals who were doubly heterozygous for the
PPP1R3A FS variant and a PPARG FS loss-of-function
mutation (Figure 1A) [1]. Both digenic participants were
glucose intolerant and markedly hyperinsulinemic (Figure 1B
and 1C).
Mice Carrying the PPP1R3A FS Mutation Have Abnormal
Glycogen Metabolism
Ppp1r3a FS mutant mice (RGL kin) were generated by
introducing the human mutation, in which deletion of two
base pairs results in six altered amino acids before encoun-
tering a stop codon [1], into the mouse Ppp1r3a locus.
Therefore, a nucleotide sequence encoding the six altered
amino acids and a stop codon were introduced at the
PLoS Medicine | www.plosmedicine.org January 2008 | Volume 5 | Issue 1 | e270115
PPP1R3A Variant Lowers Muscle Glycogen
corresponding position in the mouse gene by homologous
recombination (Figure S1). All mice used in the studies were
backcrossed three or four generations into the C57BL6/6J
background. The resulting Ppp1r3a locus contains one LoxP
site in intron 3 and the frameshift mutation in exon 4. The
predicted truncated RGL polypeptide consists of 634 residues
with a Mr of 72,000. Western blotting of skeletal muscle
extracts conﬁrmed expression of the truncated RGL (RGL
trunc) (Figure 2A), which on SDS-PAGE migrates with an
apparent Mr of 83,000, higher than predicted. This altered gel
migration is consistent with the properties of RGL, which as
the full-length form also has slower electrophoretic mobility
(160 kDa) than predicted (123 kDa). WT RGL was decreased by
;50% in knock-in heterozygotes and was absent in the
homozygotes (Figure 2A). The seemingly stronger signal of
the truncated RGL protein is a reﬂection of the lower
efﬁciency of electrophoretic transfer of the full-length
protein. From heterozygous mouse intercrosses, WT, RGL
kin heterozygotes and homozygotes were born at the
expected mendelian ratio (1:2:1; WT 35, heterozygotes 81,
and homozygotes 39). Growth, weight, and lean and fat mass
were similar in all groups of animals up to the age of 9 mo
(unpublished data).
The GS/þG6P activity ratio, which reﬂects the phosphor-
ylation and activity state of the enzyme, was signiﬁcantly
decreased in muscle of both heterozygous (45%) and
homozygous (68%) RGL kin mice (Figure 2B), whereas the
GP /þ AMP activity ratio was increased (30% and 50%
respectively) (Figure 2D). Total GS and GP activities were also
altered in the homozygous RGL kin mice (Figure 2C and 2E).
As a consequence, muscle glycogen content was signiﬁcantly
decreased in RGL kin mice (40% and 55% reduction in
heterozygotes and homozygotes, respectively) (Figure 2F).
Notably, treatment with 5 mU/g insulin resulted in a similar
extent of GS activation in WT, heterozygous, and homozygous
knock-in mice (D increase 0.05–0.07; Figure 2B) indicating
that neither the decreased glycogen level nor the truncation
of RGL have a signiﬁcant effect on GS activation by insulin. A
similar response was previously observed in the RGL knockout
mice [10]. Very low or absent muscle glycogen in RGL [10] and
GS knockout mice [16], respectively, results in activation of
AMP kinase, increased acetyl-CoA carboxylase phosphoryla-
tion, and a metabolic switch to increase muscle fatty acid
oxidation [16,17]. AMP kinase phosphorylation in the RGL kin
skeletal muscle revealed no detectable alterations (unpub-
lished data), most likely because the glycogen content in these
mice is signiﬁcantly higher than in RGL knockouts. Liver
glycogen content was similar in WT and RGL kin mice
(unpublished data).
The Mutant Protein Is Mistargeted in Mouse Skeletal
Muscle
The truncated RGL retains PP1c-, glycogen-, and putative
substrate-binding motifs, all of which are located in the ﬁrst
240 amino acids encoded by exon 1 [5,6,18]. Western blot
analyses showed that expression of PP1cd, the predominant
isoform associated with RGL, was similar in all three mouse
genotypes (Figure 3A). The level of GS was, however,
decreased (Figure 3A), in keeping with the decreased total
GS activity, most likely as a consequence of decreased
glycogen, which is required for GS stability [5]. In order to
gain insights into the mechanisms involved in the decreased
Figure 1. Human PPP1R3A FS Carrier Phenotype
(A) Muscle glycogen, (B) blood glucose, and (C) insulin levels in humans
with the PPP1R3A FS mutation before and after two standardised meals
(given at 60 and 240 min). Data from PPP1R3A FS carriers (n ¼ 4; open
circles) are compared with those from volunteers without diabetes (n¼9;
solid squares) and from participants with type 2 diabetes (T2DM; n¼ 9;
filled triangles). Mean data from two digenic participants (double
heterozygotes for the PPP1R3A FS and PPARG FS) are included in graphs
(A) and (B). Mean fasting insulin levels from the two digenic individuals
were 199, 5,744, 9,534, 1,303, 13,689, and 10,291 pmol/l, too high to
include in (C), at 0, 60, 120, 240, 360, and 480 minutes, respectively.
doi:10.1371/journal.pmed.0050027.g001
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glycogen content we assessed RGL binding to GS and
glycogen. Antibodies directed against both the N-terminal
262 residues and C-terminal 325-1042 amino acids of RGL
immunoprecipitated most of the full-length and truncated
RGL (note that the truncation is at residue 643), but did not
coimmunoprecipitate GS, indicating that neither WT nor
mutant RGL binds GS (Figure 3B and 3C). This surprising
result was conﬁrmed by the reciprocal experiment in which
GS was pulled down. We utilized a fusion protein (GST-
GN[297–333] of GST and the residues 297–333 of glycogenin
(GN), the glycogen priming protein [9], which interact with
GS in two-hybrid assays and in coexpression studies [19].
While GST-GN(297–333) pulled down GS almost completely
(Figure 4A), neither the WT nor the truncated RGL were
Figure 2. Muscle Glycogen Metabolism in RGL Knock-in and Wild-Type Mice
(A) RGL Western blots of skeletal muscle extracts from WT, RGL knock-in heterozygous (RGL kin het), and RGL knock-in homozygous (RGL kin hom) mice.
The predicted molecular weight (MW) of the truncated RGL (RGL trunc, 643 amino acids) is 72,000 but it migrates on SDS polyacrylamide gel
electrophoresis with an apparent MW of 83,000.
(B) GS activity was assayed in the absence () or presence (þ) of G6P in extracts of skeletal muscle from WT, RGL knock-in heterozygous (RGL kin het), and
RGL knock-in homozygous (RGL kin hom) mice not injected or injected intraperitoneally with 5 mU/g insulin for 10 min (plain and chequered bars,
respectively).
(C) Total GS activity (mU/mg) measured in the presence of 7.2 mM G6P.
(D) Glycogen phosphorylase (Ph) activity was assayed in the absence () or presence (þ) of 2 mM AMP.
(E) Total glycogen phosphorylase (Ph) activity (U/mg) measured in the presence of 2 mM AMP.
(F) Glycogen content in muscle.
n¼ 4–9 per group; * p , 0.05 versus WT basal; # p , 0.05 insulin versus basal.
doi:10.1371/journal.pmed.0050027.g002
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found associated with GS (Figure 4B). Finally, high-speed
ultracentrifugation was used to precipitate glycogen and
sarcoplasmic reticulum from murine muscle extracts. The
vast majority of WT RGL and GS, and a substantial proportion
of GP were recovered in the high-speed pellet, indicating that
they were all bound to glycogen (RGL also binds to
sarcoplasmic reticulum) (Figure 5). However, truncated RGL
was conﬁned to the supernatant fraction, suggesting that the
region between residue 637 and the C-terminal end of RGL
may contribute to glycogen binding in addition to associating
with sarcoplasmic reticulum. Although we cannot exclude the
possibility that the inability of the truncated RGL to sediment
in the high-speed pellet may be due to loss of the hydro-
phobic, membrane-associating domain, the fact that all the
GS, which is well known to bind to glycogen, is present in the
pellet argues that the ability of RGL trunc to bind glycogen is
decreased. In addition, after solubilising membranes with
Triton X-100 in the muscle extract, we still found a signiﬁcant
proportion of full-length RGL and all of the GS in the high-
speed pellet, while the truncated RGL was primarily in the
supernatant (Figure S3). Ultimately, the lack of colocalization
of GS and truncated RGL accounts for the decreased GS
activity and glycogen content in the mutant mice.
Figure 3. Interactions between WT RGL, RGL Knock-In Truncated Mutant
(RGL trunc), and GS in Skeletal Muscle Extracts from WT, RGL Knock-In
Heterozygous (RGL kin het) and RGL Knock-In Homozygous (RGL kin hom)
Mice
(A) Western blots of protein phosphatase-1 catalytic subunit delta
(PP1cd) and GS in muscle extracts.
(B) Western blots for RGL and GS following RGL immunoprecipitation with
a RGL N-terminal antibody (Ab).
(C) Western blots for RGL and GS following RGL immunoprecipitation with
a RGL C-terminal antibody (Ab).
doi:10.1371/journal.pmed.0050027.g003
Figure 4. Glycogen Synthase Pull Down
GS was pulled down with GST-glycogenin—GST-GN(297–333)—fusion
protein before and after a-amylase digestion of glycogen in skeletal
muscle extracts from wild type (RGL WT) and RGL knock-in homozygous
(RGL kin hom) mice. (A) GST-GN(297–333) pulls down almost all GS, but
(B) neither the WT nor the truncated RGL (RGL trunc) was pulled down by
GST-GN(297–333).
doi:10.1371/journal.pmed.0050027.g004
Figure 5. RGL Western Blot Analysis of Skeletal Muscle Extracts
Western blotting of high-speed supernatants and pellets of skeletal
muscle extracts from WT, RGL knock-in heterozygous (het), and RGL
knock-in homozygous (hom) mice. High speed (HS) ultracentrifugation at
100,0000g for 90 min was used to pellet glycogen. Western blots for RGL,
GS, and GP were then performed on the supernatant and pellet fractions.
doi:10.1371/journal.pmed.0050027.g005
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Glucose Tolerance and Insulin Sensitivity Is Normal in RGL
Knock-in Mice
Glucose and insulin tolerance were similar in male and
female WT, RGL kin heterozygotes and RGL kin homozygotes
(Figure 6A and 6B). As RGL is only expressed in muscle, we
also performed hyperinsulinemic-euglycemic clamps (with
radioisotope infusions) in order to independently assess
peripheral (predominantly muscle) and hepatic insulin
sensitivity. Glucose infusion rates, insulin-stimulated periph-
eral glucose turnover, and the ability of insulin to suppress
endogenous glucose production were similar in WT and RGL
kin heterozygous mice (Figure 6C–6F). Whole-body glycogen
synthesis and glycolysis, as well as muscle insulin-stimulated
glycogen synthesis, were also similar in both groups (Figure
6G).
Discussion
Muscle glycogen is one of two major energy sources for
muscle contraction, the other being fatty acids. The fuel
Figure 6. Glucose Tolerance and Insulin Sensitivity in RGL Knock-in Mice
(A) Glucose tolerance following intraperitoneal glucose (2 mg/g body weight) administration in WT, RGL knock-in heterozygous (RGL kin het), and RGL kin
homozygous (RGL kin hom) mice.
(B) Plasma glucose response to intraperitoneal insulin (0.75 mU/g body weight) in WT-, RGL knock-in heterozygous (RGL kin het)-, and RGL knock-in
homozygous (RGL kin hom) mice. Peripheral and hepatic insulin sensitivity were assessed by means of hyperinsulinemic-euglycemic clamps in WT and
RGL kin het mice (C–G). Glucose infusion rates (C); peripheral glucose turnover (D); and basal (E) and suppressed (F) endogenous glucose production
(EGP) during hyperinsulinemic-euglycemic clamps.
(G) Whole body (WB) glycolysis and glycogen synthesis were measured during the clamps.
Data are expressed as mean values 6 SEM for 6–9 mice per treatment group.
doi:10.1371/journal.pmed.0050027.g006
PLoS Medicine | www.plosmedicine.org January 2008 | Volume 5 | Issue 1 | e270119
PPP1R3A Variant Lowers Muscle Glycogen
utilized by muscle depends on factors such as the type,
intensity and duration of exercise, glycogen being primarily
used during short bursts of high-intensity exercise [20].
Glycogen turnover is tightly regulated by two enzymes, GS
and GP. PP1 catalyzes the dephosphorylation of GS and GP,
thereby activating GS, inactivating GP, and promoting net
glycogen synthesis [7,8]. Its activity is regulated by a large
family of targeting subunits, of which RGL is the major
glycogen targeting subunit in muscle [21]. Several human
genetic disorders of glycogen metabolism have been de-
scribed affecting muscle alone or muscle, liver, and other
tissues. Until very recently, all of those affecting muscle alone
impaired glycogen breakdown and caused either episodic
exercise intolerance or ﬁxed, progressive muscle weakness
[20]. Kollberg et al. [22] described a consanguineous kindred
in which three individuals were homozygous for premature
stop mutations in GYS1. Affected family members presented
in childhood with hypertrophic cardiomyopathy (which
appeared to cause sudden death in one case) and exercise
intolerance. Muscle histology revealed severe glycogen
depletion and a marked increase in mitochondria-rich type
1 ﬁbres. Glucose tolerance appeared to be normal in the
single individual in whom it was assessed. This human
phenotype is similar to that of the GYS1 knockout mice
[16,23]. A number of mutations in PPP1R3A have been
identiﬁed in humans but, to date, none have been convinc-
ingly linked to in vivo alterations in glycogen metabolism
[9,24–27]. We genotyped 744 nondiabetic adults from the
Oxford Biobank in order to (1) assess prevalence rates of the
PPP1R3A FS variant in an unselected population and (2)
identify carriers of the variant whom we might approach for
phenotyping. Prevalence ﬁgures of 1.46% are consistent with
our original observation of 1.36% prevalence in a Cam-
bridgeshire-based study [1]. Fasting and postprandial muscle
glycogen levels were signiﬁcantly decreased in nondiabetic
PPP1R3A FS carriers, making this the second genetic
condition known to speciﬁcally reduce muscle glycogen
accumulation.
In order to precisely delineate the molecular consequences
of the PPP1R3A FS variant we generated a knock-in mouse
model, carrying the human mutation. RGL kin mice were
healthy, reproductively viable, and of normal body weight
and fat mass, but like human carriers, had signiﬁcantly
decreased skeletal muscle glycogen levels. Although the
truncated RGL is expressed at levels similar to the WT allele
and retains its capacity to bind PP1c, muscle GS activity was
signiﬁcantly decreased in RGL kin mice and GP activity was
increased. In contrast to the apparent susceptibility to
degradation of an adenovirally expressed 375-residue RGL
fragment [28], we did not detect any evidence of degradation
of our 634 amino acid FS variant. It is important to note that
degradation was observed by Lerin et al. [28] only when cells
were grown under nonphysiological conditions of zero
glucose, a state that does not occur in humans and mice.
The reduction in GS activity is nicely explained by the failure
of truncated RGL to colocalize with GS and therefore to direct
PP1c phosphatase activity to GS. As GS is largely bound to
glycogen, the inability of the truncated RGL to colocalize with
GS, despite the fact that it retains the glycogen-binding
domain, suggests that the glycogen-binding afﬁnity of
truncated RGL is decreased.
This observation is somewhat surprising, but several
alternative explanations can be advanced. First, although
the glycogen-binding domain in RGL is essential it may not be
sufﬁcient and additional sites in the C-terminal third of the
protein may also be involved in glycogen binding. Second,
deletion of the C-terminal third of the protein may affect the
overall protein conformation, impairing binding to glycogen.
Third, it is possible that association with the sarcoplasmic
reticulum is critical for glycogen binding, since our truncated
RGL lacks the C-terminal hydrophobic segment and cannot
associate with sarcoplasmic reticulum [1]. However, the
sedimentation of full-length RGL and GS, but not truncated
RGL, in the high-speed pellet after Triton X-100 solubilisation
(Figure S3), argues that binding of the full-length form to
glycogen is independent of sarcoplasmic reticulum associa-
tion. Contrary to previous proposals [18], we also provide
compelling evidence that GS does not stably interact with RGL
in the physiological tissue. Studies implicating a direct
interaction between RGL and GS utilized nonphysiological
and overexpressing systems [17]. We used both coimmuno-
precipitation and GST pull-down assays to show that neither
full length nor truncated RGL binds GS. These observations
support the notion that the basic function of RGL is to target
PP1c to glycogen, thereby promoting dephosphorylation of
glycogen bound GS and GP, a catalytic process that does not
require stable interaction.
Given that the PPP1R3A FS variant is prevalent in UK white
populations and that human physiological studies strongly
implicate impaired insulin-stimulated glycogen synthesis in
the pathogenesis of insulin-resistant type 2 diabetes [29,30], is
there any evidence that it is a signiﬁcant ‘‘diabetes genetic
variant’’? We originally identiﬁed the PPP1R3A FS mutation
in a large kindred with severe insulin resistance and type 2
diabetes [1]. In that kindred only those individuals harbour-
ing a second unlinked mutation in PPARG were severely
insulin resistant. The PPARG mutation is a loss-of-function
mutation, but did not manifest dominant negative activity,
which is a feature of the other PPARG variants shown to be
associated with partial lipodystrophy and severe insulin
resistance [31]. In a second family, weight gain appeared to
induce disproportionate insulin resistance in PPP1R3A FS
carriers [1]. Taken together, these data suggest that carriers of
the PPP1R3A FS variant may be predisposed to develop
severe insulin resistance in the setting of adipose tissue
dysfunction.
In an effort to replicate this interaction in mice, we crossed
RGL kin mice with PPARc heterozygous knockouts [32] but
the double heterozygosity failed to alter glucose tolerance or
insulin sensitivity (Figure S4). Mouse and human muscle
glycogen metabolism is very different (mouse glycogen
content is much lower than that of human muscle), and the
phenotype of PPARc haploinsufﬁcient mice is very different
to that of humans with the PPARG FS variant. PPARc þ/
mice are protected against diet- and age-induced insulin
resistance [32], whereas humans with the PPARG FS variant,
which appears to behave as a null allele [31], manifest
exaggerated hypertriglyceridaemia and insulin resistance
with weight gain (unpublished data). Our original studies in
Cambridgeshire volunteers did involve individuals with type 2
diabetes and controls, and the variant was signiﬁcantly (p ¼
0.03) enriched in the diabetic group [1]. However, given a
population prevalence of ;1.46% and an apparently subtle
phenotype, it will require very large population-based studies
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in multiple ethnic groups to determine whether it has a
signiﬁcant impact on type 2 diabetes. The PPP1R3A FS
variant is not captured by existing ﬁxed single nucleotide
polymorphism arrays, so one cannot infer anything about its
impact on diabetes risk from the recently reported type 2
diabetes genomewide association studies [33]. The FS
mutation could also have functional implications for skeletal
muscle performance. Anecdotally, human carriers of the
PPP1R3A FS variant do not report exercise intolerance or
muscle weakness. Studies of exercise tolerance combined with
stable isotope tracing of metabolic ﬂuxes will be needed to
formally address this question in humans.
In summary, we have identiﬁed a PPP1R3A FS variant,
which encodes a truncated protein that is mistargeted within
the cell, that decreases muscle GS activity, and that increases
phosphorylase activity, thereby decreasing muscle glycogen
content in humans and mice. This metabolic change by itself
does not alter glucose tolerance or insulin sensitivity. The
ﬁndings are notable because this is a prevalent genetic
mutation that clearly impairs muscle glycogen synthesis in
humans. These data also demonstrate that functionally
important mutations occurring at appreciable population
frequencies contribute to the genetic architecture of human
metabolic variation.
Supporting Information
Figure S1. Strategy for the Generation of the Frameshift Mutant
Mouse Ppp1r3a Locus
Found at doi:10.1371/journal.pmed.0050027.sg001 (16 KB PDF).
Figure S2. Generation of Mice with the Ppp1r3a (RGL) Frameshift
Mutation
(A) Southern blots of initially targeted embryonic stem (ES) cell
clones and after Cre recombinase excision of the Neo cassette. Two
targeted clones were originally obtained, 1 and 2, which were
analyzed by Southern blotting.
(B) After excision of the Neo cassette, six subclones from each
original were analyzed by Southern blotting. Two each are shown.
(C) PCR genotyping of WT, heterozygous (het), and homozygous
(hom) RGL knock-in (kin) mice with a pair of primers straddling the
residual loxP site or with a pair of primers that speciﬁcally recognize
the frameshift mutation. AhdI, Ah; BStz171, Bs; EcoRv, Ec; NcoI, Nc;
NheI, Nh; NotI, No; Truncated, Tg, XhoI, Xh.
Found at doi:10.1371/journal.pmed.0050027.sg002 (133 KB PDF).
Figure S3. Western Blots of Muscle Extracts
Muscle extracts were prepared in the presence of 0.2% Triton X-100
to solubilise membranes. High speed (HS) ultracentrifugation at
100,000g for 90 min was used to pellet glycogen before Western
blotting of supernatant and pellet fractions for full-length and
truncated mutant (trunc) RGL and GS in samples from WT,
heterozygous RGL knock-in (het), and homozygous RGL knock-in
(hom) mice.
Found at doi:10.1371/journal.pmed.0050027.sg003 (71 KB PDF).
Figure S4. Glucose and Insulin Tolerance Tests
Glucose tolerance tests (A) and insulin tolerance tests (B) in WT, RGL
knock-in heterozygotes (RGL kin het), PPARc heterozygous knockouts
(PPARgþ/), and doubly heterozygous mice. n ¼ 7–8 per group.
Found at doi:10.1371/journal.pmed.0050027.sg004 (16 KB PDF).
Text S1. Supplementary Experimental Procedures
Found at doi:10.1371/journal.pmed.0050027.sd001 (48 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/) accession numbers of the
genes discussed in this paper are PPP1R3 (AF024578; Homo sapiens
type-1 protein phosphatase skeletal muscle glycogen) and Ppp1r3a
(AF309628 and AF309629; Mus musculus type 1 protein phosphatase
targeting subunit RGL/ GM gene).
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Editors’ Summary
Background. The human body gets the energy it needs for day-to-day
living from food in a process called metabolism. However, not all the
energy released by metabolism is used immediately. Some is stored in
skeletal muscles as glycogen, a glucose polymer that is used during high
intensity exercise. After eating, chemicals in the digestive system release
glucose (a type of sugar) from food into the bloodstream where it
triggers insulin release from the pancreas. Insulin instructs muscle, liver
and fat cells to remove glucose from the bloodstream to keep the
amount of sugar in the blood at a safe level. The cells use the glucose
immediately as fuel or convert it into glycogen or fat for storage.
Glycogen turnover (the depletion and replacement of glycogen stores) is
tightly controlled by glycogen synthase and glycogen phosphorylase,
enzymes that make and destroy glycogen, respectively. A third enzyme
called protein phosphatase 1 promotes net glycogen synthesis by
activating glycogen synthase and inactivating glycogen phosphorylase.
The activity of protein phosphatase 1 is regulated by a family of
‘‘targeting subunits.’’ In muscle, one of these targeting subunits, called
RGL, facilitates protein phosphatase 1 action on glycogen synthase and
glycogen phosphorylase.
Why Was This Study Done? Several known human genetic disorders
affect the breakdown of muscle glycogen but few genetic changes
(mutations) have been found that decrease the synthesis of muscle
glycogen. Researchers are interested in discovering mutations that affect
glycogen turnover and other aspects of metabolism because some of
these may be involved in the development of diabetes, an important
metabolic disorder characterized by high blood sugar levels. In this
study, the researchers have investigated how a recently identified
mutation in PPP1R3A, the gene that encodes RGL, affects glycogen
synthesis. This mutation—PPP1R3A FS—was previously found in 1.36% of
a UK white population. It causes the production of a short version of RGL
that lacks the part of the molecule that tethers RGL to a cellular structure
called the sarcoplasmic reticulum but leaves its glycogen binding
domain intact.
What Did the Researchers Do and Find? To confirm that PPP1R3A FS is
a common mutation in the UK white population, the researchers
sequenced the gene in 744 healthy adults enrolled in the Oxford Biobank
(which hopes to uncover metabolically important genetic variations by
monitoring the health of a large number of 30- to 50-year-old people
from whom DNA has been collected). 1.46% of these people had the
PPP1R3A FS mutation. To examine glycogen storage in carriers of the
mutation, the researchers used a technique called in vivo 13C magnetic
resonance spectroscopy. Basal muscle glycogen levels and those reached
after a meal were lower in these individuals than in people without the
mutation but their blood sugar and insulin levels were normal. Finally, to
examine how the mutation reduces muscle glycogen, the researchers
made mice carrying the PPP1R3A FS mutation. Like the human carriers,
these mice had less glycogen than normal in their muscles. Unexpect-
edly, in biochemical experiments the truncated RGL protein made by the
mutant mice did not bind to glycogen or co-localize with glycogen
synthase. This lack of binding decreased the activity of glycogen
synthase and increased the activity of glycogen phosphorylase, thus
decreasing muscle glycogen.
What Do These Findings Mean? These findings identify the PPP1R3A FS
mutation as the first prevalent mutation known to impair glycogen
synthesis and to decrease glycogen levels in human skeletal muscles.
They also confirm that this mutation is very common in UK whites.
Although these human carriers do not report any exercise intolerance,
detailed studies are needed to test whether the mutation has any effect
on skeletal muscle performance. In addition, suggest the researchers, the
mutation might be involved in the development of type 2 diabetes.
Impaired insulin-stimulated glycogen synthesis, which is a feature of
insulin-resistant muscle and liver cells, is thought to be a key event in the
development of type 2 diabetes. Although some previous results
indicate that the PPP1R3A FS mutations can sometimes predispose
people to develop insulin resistance, only a large population-based study
in multiple ethnic groups will reveal whether the PPP1R3A FS mutation
has an important impact on the development of type 2 diabetes.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050027.
 Wikipedia has pages on metabolism and on glycogen (note that
Wikipedia is a free online encyclopedia that anyone can edit; available
in several languages)
 The MedlinePlus encyclopedia provides information about diabetes (in
English and Spanish)
 The UK Biobank is looking for genetic variations among human
populations that are associated with metabolic and other disorders
 Web sites are available with brief descriptions of the research
programs of Stephen O’Rahilly and Anna DePaoli-Roach
PLoS Medicine | www.plosmedicine.org January 2008 | Volume 5 | Issue 1 | e270122
PPP1R3A Variant Lowers Muscle Glycogen
